LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Cell Count Performed at Bedside with Innovative Biochip

By LabMedica International staff writers
Posted on 05 Jan 2016
Print article
Image: Photomicrograph of a blood film showing various leukocytes as part of a differential count (Photo courtesy of the University of Utah).
Image: Photomicrograph of a blood film showing various leukocytes as part of a differential count (Photo courtesy of the University of Utah).
There is a great need for an automated, portable point-of-care blood cell counter that could yield results in a matter of minutes from a drop of blood without any trained professionals to operate the instrument.

Expensive hematology analyzers are currently used as a gold standard for acquiring complete blood cell counts (CBCs) and for nearly all CBCs performed today, the patient must travel to either a hospital with a large laboratory or to a centralized laboratory testing facility.

Scientists at the University of Illinois at Urbana-Champaign (UIUC; Champaign, IL, USA) developed microfluidic biochips capable of a partial CBC using only a drop of whole blood. Total leukocyte and their 3-part differential count are obtained from 10 mL of blood after on-chip lysing of the red blood cells (RBCs) and counting of the leukocytes electrically using microfabricated platinum electrodes. For RBCs and platelets, one mL of whole blood is diluted with phosphate buffered saline (PBS) on-chip and the cells are counted electrically. The total time for measurement is under 20 minutes.

The team is already developing a portable prototype of the cell counter. The base unit of the reader will likely be hand-held and will take cartridges about the size of a credit card. They estimate the cost of a test will be around USD 10 instead of the USD 100 that a current test costs. The technology is scalable and the team also plans to investigate using it in other areas, such as animal diagnostics, blood transfusion analysis, and blood cell counting for managing chemotherapy treatments.

Umer Hassan, PhD, the first author of the study and an expert in bioelectronics, said, “There is huge potential for commercializing the technology and the translation of our technology will result in minimal to no experience requirement for device operation. Even, patients can perform the test at the comfort of their home and share the results with their primary care physicians via electronic means too.” The study was published on December 11, 2015, in the journal Technology.

Related Links:

University of Illinois at Urbana-Champaign 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.